InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Discover the complete record of transactions filed by Caeymaex Emmanuel, Dirigeant. Officer active across 1 companies, notably UCB. Cumulatively, 14 disclosures have been logged. The latest transaction was disclosed on 8 April 2026 — Purchase. Regulator: FSMA. All data is free.
Declarations14 total
€809,8917,937 shares@ €102.040.0018% mcap11.2% of flow
ShareOff exchange
FSMA:ucb-86·
Ideal exit: 3 Jan 2027 (T+270)
€274,5181,010 shares@ €271.800.0006% mcap3.8% of flow
ShareEuronext Brussels
FSMA:ucb-62·
€2m7,937 shares@ €266.700.0047% mcap29.4% of flow
ShareEuronext Brussels
FSMA:ucb-33·
04,031 shares0
Options /warrants for employees or managersOff exchange
FSMA:ucb-129·
Ideal exit: 2 Jan 2027 (T+270)
03,528 shares0
ShareOff exchange
FSMA:ucb-60·
Ideal exit: 27 Dec 2026 (T+270)
€239,9703,000 shares@ €79.990.0005% mcap3.3% of flow
ShareOff exchange
FSMA:ucb-187·
Ideal exit: 5 Oct 2026 (T+270)
€762,8133,000 shares@ €254.270.0017% mcap10.6% of flow
ShareEuronext Brussels
FSMA:ucb-198·
€73,619966 shares@ €76.210.0002% mcap1.0% of flow
ShareOff exchange
FSMA:ucb-179·
Ideal exit: 15 Sept 2026 (T+270)
€230,391966 shares@ €238.500.0005% mcap3.2% of flow
ShareEuronext Brussels
FSMA:ucb-226·
€714,9003,000 shares@ €238.300.0016% mcap9.9% of flow
ShareEuronext Brussels
FSMA:ucb-112·
€239,9703,000 shares@ €79.990.0005% mcap3.3% of flow
ShareOff exchange
FSMA:ucb-191·
Ideal exit: 15 Sept 2026 (T+270)
€373,3501,500 shares@ €248.900.0008% mcap5.2% of flow
ShareEuronext Brussels
FSMA:ucb-52·
€371,4751,500 shares@ €247.650.0008% mcap5.2% of flow
ShareEuronext Brussels
FSMA:ucb-183·
€1m5,000 shares@ €200.680.0022% mcap13.9% of flow
ShareEuronext Brussels
FSMA:ucb-128·
14 of 14 declarations
About Caeymaex Emmanuel
Emmanuel Caeymaex is a senior executive at UCB, a global biopharmaceutical company. In his role, he is responsible for the strategic direction and management of the company's operations. Caeymaex plays a key role in developing innovative solutions for patients, focusing on research and development. His experience in the pharmaceutical industry enables him to contribute effectively to UCB's evolution in the global market.
